Lung Cancer Clinical Trial

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Summary

A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer

View Full Description

Full Description

This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable EGFR mutation-positive NSCLC, including the most common EGFR sensitising mutations (Ex19Del and L858R), either alone or in combination with other EGFR mutations. Chemoradiation may have been given either given concurrently or sequentially. Patients whose disease has not progressed following chemoradiation will be randomised within 6 weeks of completion of chemoradiation to receive osimertinib or placebo in a 2:1 ratio, and treatment will be continued until disease progression, unacceptable toxicity or other discontinuation criteria are met. After progression, patients can be unblinded and may receive open-label osimertinib. After the final OS analysis, the study blind will be broken and patients still receiving open-label osimertinib will be supplied with open-label osimertinib by AstraZeneca for as long as their treating physician considers they are deriving clinical benefit.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

Male or female aged at least 18 years.
Patients with histologically documented NSCLC of predominantly non-squamous Pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology).
The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test in a CLIA certified (USA sites) or an accredited local laboratory (sites outside of the USA) or by central testing (cobas® v2 only).
Patients must have received either concurrent chemoradiation or sequential chemoradiation including at least 2 cycles of platinum based chemotherapy and a total dose of radiation of 60 Gy ±10% (54 to 66 Gy).
Chemoradiation must be completed ≤6 weeks prior to randomization.
Patients must not have had disease progression during or following definitive platinum-based, chemoradiation therapy.
World Health Organization (WHO) performance status of 0 or 1.
Life expectancy >12 weeks at Day 1.
Female patients who are not abstinent (in line with the preferred and usual lifestyle choice) must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-childbearing potential.

Exclusion Criteria

Mixed small cell and non-small cell lung cancer histology
History of interstitial lung disease (ILD) prior to chemoradiation
Symptomatic pneumonitis following chemoradiation
Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) > Grade 2 from the prior chemoradiation therapy

Any of the following cardiac criteria:

Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs
Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
Inadequate bone marrow reserve or organ function
History of other malignancies, except: adequately treated non-melanoma skin cancer or lentigo maligna , curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
Prior treatment with any prior chemotherapy, radiation therapy, immunotherapy or investigational agents for NSCLC outside of that received in the definitive setting for Stage III disease (chemotherapy and radiotherapy in SCRT and CCRT regimens is allowed for treatment of Stage III disease).
Prior treatment with EGFR-TKI therapy
Major surgery as defined by the investigator within 4 weeks of the first dose of study drug.
Patients currently receiving (unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior to receiving the first dose of study drug).
Contraindication to MRI, including but not limited to, claustrophobia, pace makers, metal implants, intracranial surgical clips and metal foreign bodies

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

216

Study ID:

NCT03521154

Recruitment Status:

Active, not recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 111 Locations for this study

See Locations Near You

Research Site
Duarte California, 91010, United States
Research Site
Atlanta Georgia, 30322, United States
Research Site
Florham Park New Jersey, 07932, United States
Research Site
Salt Lake City Utah, 84106, United States
Research Site
Madison Wisconsin, 53792, United States
Research Site
Ciudad Autónoma de Bs. As. , 1426, Argentina
Research Site
Ciudad Autónoma de Bs. As. , C1199, Argentina
Research Site
Mar del Plata , 7600, Argentina
Research Site
Rosario , 2000, Argentina
Research Site
San Salvador de Jujuy , 4600, Argentina
Research Site
Barretos , 14784, Brazil
Research Site
Campinas , 13060, Brazil
Research Site
Curitiba , 81520, Brazil
Research Site
Florianópolis , 88034, Brazil
Research Site
Fortaleza , 60336, Brazil
Research Site
Porto Alegre , 90160, Brazil
Research Site
Porto Alegre , 90610, Brazil
Research Site
Ribeirão Preto , 14021, Brazil
Research Site
Sao Paulo , 01221, Brazil
Research Site
Sao Paulo , 01246, Brazil
Research Site
Beijing , 10002, China
Research Site
Beijing , 10073, China
Research Site
Changchun , 13000, China
Research Site
Changsha , 41001, China
Research Site
Chengdu , 61004, China
Research Site
Guangzhou , 51010, China
Research Site
Hangzhou , 31000, China
Research Site
Hangzhou , 31000, China
Research Site
Hangzhou , 31002, China
Research Site
Jinan , 25011, China
Research Site
Linhai , 31700, China
Research Site
Shanghai , 20003, China
Research Site
Shanghai , 20003, China
Research Site
Urumqi , 83009, China
Research Site
Wuhan , 43002, China
Research Site
Wuhan , 43003, China
Research Site
Budapest , 1083, Hungary
Research Site
Budapest , 1121, Hungary
Research Site
Gyöngyös - Mátraháza , 3200, Hungary
Research Site
Pécs , 7623, Hungary
Research Site
Bangalore , 56006, India
Research Site
Gurgaon , 12200, India
Research Site
Hubli , 58002, India
Research Site
Karamsad , 38832, India
Research Site
Kolkata , 70016, India
Research Site
Nashik , 42200, India
Research Site
New Delhi , 11006, India
Research Site
New Delhi , 11008, India
Research Site
New Delhi , 11029, India
Research Site
Hiroshima-shi , 734-8, Japan
Research Site
Kanazawa-shi , 920-8, Japan
Research Site
Kashiwa , 227-8, Japan
Research Site
Nagoya-shi , 460-0, Japan
Research Site
Niigata-shi , 951-8, Japan
Research Site
Osaka-shi , 541-8, Japan
Research Site
Osakasayama , 589-8, Japan
Research Site
Sakai-shi , 591-8, Japan
Research Site
Sapporo-shi , 003-0, Japan
Research Site
Sendai-shi , 980-0, Japan
Research Site
Shinjuku-ku , 160-0, Japan
Research Site
Sunto-gun , 411-8, Japan
Research Site
Yokohama-shi , 241-8, Japan
Research Site
Cheongju-si , 28644, Korea, Republic of
Research Site
Incheon , 21565, Korea, Republic of
Research Site
Seongnam-si , 13620, Korea, Republic of
Research Site
Seoul , 05505, Korea, Republic of
Research Site
Seoul , 06351, Korea, Republic of
Research Site
George Town , 10450, Malaysia
Research Site
Kuala Lumpur , 59100, Malaysia
Research Site
Selangor , 46050, Malaysia
Research Site
Mérida , 97134, Mexico
Research Site
Lima , LIMA , Peru
Research Site
Lima , Lima , Peru
Research Site
Lima , LIMA , Peru
Research Site
Lima , LIMA , Peru
Research Site
San Isidro , 27, Peru
Research Site
Kazan , 42002, Russian Federation
Research Site
Kostroma , 15600, Russian Federation
Research Site
Moscow , 12120, Russian Federation
Research Site
Novisibirsk , 63008, Russian Federation
Research Site
Obninsk , 24903, Russian Federation
Research Site
Saint-Petersburg , 19435, Russian Federation
Research Site
Saint-Petersburg , 19702, Russian Federation
Research Site
Saint-Petersburg , 19775, Russian Federation
Research Site
Ufa , 45005, Russian Federation
Research Site
Barcelona , 08003, Spain
Research Site
Madrid , 28040, Spain
Research Site
Madrid , 28046, Spain
Research Site
Málaga , 29010, Spain
Research Site
San Sebastián , 20014, Spain
Research Site
Sevilla , 41009, Spain
Research Site
Valencia , 46009, Spain
Research Site
Kaohsiung , 83301, Taiwan
Research Site
Taichung City , 402, Taiwan
Research Site
Taichung , 40447, Taiwan
Research Site
Taichung , 40705, Taiwan
Research Site
Tainan City , 70403, Taiwan
Research Site
Taipei , 10002, Taiwan
Research Site
Taipei , 11217, Taiwan
Research Site
Taoyuan , 00333, Taiwan
Research Site
Bangkok , 10300, Thailand
Research Site
Bangkok , 10330, Thailand
Research Site
Bangkok , 10400, Thailand
Research Site
Bangkok , 10700, Thailand
Research Site
Hat Yai , 90110, Thailand
Research Site
Khon Kaen , 40002, Thailand
Research Site
Lampang , 52000, Thailand
Research Site
Mueang , 50200, Thailand
Research Site
Adana , 01120, Turkey
Research Site
Adapazari , 54290, Turkey
Research Site
Ankara , 06280, Turkey
Research Site
Ankara , 6200, Turkey
Research Site
Ankara , , Turkey
Research Site
Istanbul , 34030, Turkey
Research Site
Istanbul , 34854, Turkey
Research Site
Izmir , 35620, Turkey
Research Site
Hanoi City , 10000, Vietnam
Research Site
Hanoi , 10000, Vietnam
Research Site
Hcmc , 70000, Vietnam
Research Site
Ho Chi Minh , 70000, Vietnam
Research Site
Ho Chi Minh , 70000, Vietnam

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

216

Study ID:

NCT03521154

Recruitment Status:

Active, not recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.